KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Short-term Investments (2023 - 2025)

Biocryst Pharmaceuticals' Short-term Investments history spans 9 years, with the latest figure at $185.0 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 14.4% year-over-year to $185.0 million; the TTM value through Dec 2025 reached $185.0 million, down 14.4%, while the annual FY2025 figure was $185.0 million, 14.4% down from the prior year.
  • Short-term Investments reached $185.0 million in Q4 2025 per BCRX's latest filing, up from $128.8 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $278.3 million in Q4 2023 to a low of $128.8 million in Q3 2025.
  • Average Short-term Investments over 3 years is $216.9 million, with a median of $224.7 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: increased 3.79% in 2024, then crashed 44.76% in 2025.
  • A 3-year view of Short-term Investments shows it stood at $278.3 million in 2023, then fell by 22.35% to $216.1 million in 2024, then dropped by 14.4% to $185.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Short-term Investments are $185.0 million (Q4 2025), $128.8 million (Q3 2025), and $172.0 million (Q2 2025).